Tyra Biosciences reported initial Phase 2 results for dabogratinib in bladder cancer, showing a 57% complete response rate at 60mg, which was significantly below analyst expectations of 70-80%. This unexpected outcome led to a sharp decline in the company's stock price, despite the data still supporting advancement to Phase 3 studies.
Tyra Biosciences released initial Phase 2 results for its drug dabogratinib in non-muscle invasive bladder cancer. While the trial established a clinical proof of concept and identified a 60mg dose for registrational studies, the complete response rate of 57% at this dose fell short of analyst expectations of 70-80%. This discrepancy triggered a significant sell-off in TYRA shares, as investors recalibrate their outlook for the drug's potential. Despite the immediate negative reaction, analysts still believe the data supports progression to Phase 3, suggesting a viable long-term path, but the short-term impact is clearly negative due to unmet expectations.